Summary: A Mayo Clinic-led international study utilized CRISPR-Cas9 technology to classify 91% of BRCA2 variants of uncertain significance, improving genetic testing and risk assessment for hereditary cancers. Takeaways: Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have advanced the understanding of genetic alterations in the BRCA2 gene, … Continue reading Advancing BRCA2 Variant Classification to Enhance Hereditary Cancer Care